Literature DB >> 20140445

Remote cerebral hematomas in patients treated with intravenous rt-PA.

Eugenia Martínez-Hernández1, Sergi Martínez-Ramírez, Raquel Delgado-Mederos, Daniel Alcolea, Marta Marquié, Rebeca Marín, Manuel De Juan, Josep Lluis Martí-Vilalta, Joan Martí-Fàbregas.   

Abstract

The frequency, clinical presentation, radiological features, and prognosis of remote cerebral hematomas (rPH) are not well known. We report our experience in patients treated with intravenous rt-PA. We reviewed our database of consecutive patients treated at our hospital from 1999 to 2008. We used the inclusion/exclusion criteria of the ECASS-2 study from 1999 to 2003, and the criteria of the SITS-MOST study since 2004. A follow-up CT scan was obtained in all of the patients within the first 36 h of treatment. Cerebral hemorrhagic complications were classified as hemorrhagic infarction (HI-1/HI-2) and parenchymal hematoma (PH-1/PH-2). The rPH was defined as any extra-ischemic hemorrhagic lesion observed in the follow-up CT. A favorable outcome was defined as a score 0-1 on the Rankin scale at 3 months. We treated 210 patients (mean age 67.6 +/- 12.4 years, 56% were men). The median initial NIHSS score was 14. Patients with rPH (n = 7) had a mean age of 72.4 +/- 7.5 years and 43% were men. The median initial NIHSS score was 15. Three patients had multifocal rPH; three patients had a single rPH and in one patient the rPH was associated with a PH-2. rPH were lobar in six patients and in brainstem in one patient, symptomatic in five patients and asymptomatic in two patients. The outcome was unfavorable in all of them; four deaths (57%) were recorded. Remote cerebral hemorrhage is an infrequent complication after rt-PA treatment (3.3%), it is usually lobar and symptomatic and has an uniformly unfavorable outcome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20140445     DOI: 10.1007/s00415-010-5462-2

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  18 in total

1.  Frequency and predictors of symptomatic intracerebral hemorrhage in patients with ischemic stroke treated with recombinant tissue plasminogen activator outside clinical trials.

Authors:  Joan Martí-Fàbregas; Yolanda Bravo; Dolores Cocho; Josep-Lluis Martí-Vilalta; Jordi Díaz-Manera; Luis San Román; Mireia Puig; Miguel Blanco; Mar Castellanos; Mónica Millán; Jaume Roquer; Víctor Obach; José Maestre
Journal:  Cerebrovasc Dis       Date:  2006-11-15       Impact factor: 2.762

2.  Intravenous alteplase for ischaemic stroke.

Authors:  Gregory W Albers; Jean-Marc Olivot
Journal:  Lancet       Date:  2007-01-27       Impact factor: 79.321

3.  Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage.

Authors:  A M Lopez-Yunez; A Bruno; L S Williams; E Yilmaz; C Zurrú; J Biller
Journal:  Stroke       Date:  2001-01       Impact factor: 7.914

4.  Clinical and imaging predictors of intracerebral haemorrhage in stroke patients treated with intravenous tissue plasminogen activator.

Authors:  L Derex; M Hermier; P Adeleine; J-B Pialat; M Wiart; Y Berthezène; F Philippeau; J Honnorat; J-C Froment; P Trouillas; N Nighoghossian
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-01       Impact factor: 10.154

5.  Acetylsalicylic acid pretreatment, concomitant heparin therapy and the risk of early intracranial hemorrhage following systemic thrombolysis for acute ischemic stroke.

Authors:  Susanne Schmülling; Jobst Rudolf; Timm Strotmann-Tack; Martin Grond; Susanne Schneweis; Jan Sobesky; Alexander Thiel; Wolf-Dieter Heiss
Journal:  Cerebrovasc Dis       Date:  2003       Impact factor: 2.762

6.  Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. The NINDS t-PA Stroke Study Group.

Authors: 
Journal:  Stroke       Date:  1997-11       Impact factor: 7.914

Review 7.  Cerebral amyloid angiopathy and thrombolysis-related intracerebral haemorrhage.

Authors:  Mark O McCarron; James A R Nicoll
Journal:  Lancet Neurol       Date:  2004-08       Impact factor: 44.182

8.  Risk for symptomatic intracerebral hemorrhage after thrombolysis assessed by diffusion-weighted magnetic resonance imaging.

Authors:  Oliver C Singer; Marek C Humpich; Jens Fiehler; Gregory W Albers; Maarten G Lansberg; Andiras Kastrup; Alex Rovira; David S Liebeskind; Achim Gass; Charlotte Rosso; Laurent Derex; Jong S Kim; Tobias Neumann-Haefelin
Journal:  Ann Neurol       Date:  2008-01       Impact factor: 10.422

9.  Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: the Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experience.

Authors:  M A Sloan; T R Price; C K Petito; A M Randall; R E Solomon; M L Terrin; J Gore; D Collen; N Kleiman; F Feit
Journal:  Neurology       Date:  1995-04       Impact factor: 9.910

10.  Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke.

Authors:  Joan Montaner; Carlos A Molina; Jasone Monasterio; Sonia Abilleira; Juan F Arenillas; Marc Ribó; Manolo Quintana; José Alvarez-Sabín
Journal:  Circulation       Date:  2003-02-04       Impact factor: 29.690

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.